Who is sponsoring NCT01522456?

NCT01522456 is sponsored by Galderma R&D.

What condition does NCT01522456 study?

NCT01522456 studies Acne Vulgaris.

What drugs are being tested in NCT01522456?

Interventions: Epiduo Gel, Retin-A Micro Microsphere 0.1%.

What is the status of NCT01522456?

NCT01522456 is currently COMPLETED.

Last reviewed 2022-07-28 · How we verify

Split-face Tolerability Comparison Between Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Versus Retin-A Micro® (Tretinoin Gel) Microsphere, 0.1% in Subjects With Acne Vulgaris

NCT01522456 Phase 4 COMPLETED Results posted

To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.

Details

Lead sponsor	Galderma R&D
Phase	Phase 4
Status	COMPLETED
Enrolment	73
Start date	2012-04
Completion	2012-05

Conditions

Acne Vulgaris

Interventions

Epiduo Gel
Retin-A Micro Microsphere 0.1%

Primary outcomes

Worst Postbaseline Tolerability (Erythema) — Day 1 - Day 22
Worst postbaseline tolerability assessment for erythema.
Worst Postbaseline Tolerability (Scaling) — Day 1 - Day 22
Worst postbaseline assessment for scaling.
Worst Postbaseline Tolerability (Dryness) — Day 1 - Day 22
Worst postbaseline tolerability assessments for dryness.
Worst Postbaseline Tolerability (Stinging/Burning) — Day 1 - Day 22
Worst postbaseline tolerability assessments for stinging/burning

Countries

United States